Guaifenesin-DM NR Liquid is a clear yellow liquid with a raspberry flavor.
Each 5 mL (1 teaspoonful) contains:
Guaifenesin 100 mg.
Dextromethorphan Hydrobromide 10 mg.
GUAIFENESIN-DM NR LIQUID (Guaifenesin/Dextromethorphan) is indicated for the following:
Temporarily relieves cough due to minor throat and bronchial irritation as may occur with the common cold or inhaled irritants. Calms the cough control center and relieves coughing. Helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus, drain bronchial tubes, and make coughs more productive.
Media Articles Related to Guaifenesin-DM NR Liquid (Guaifenesin / Dextromethorphan)
DC Week: Payment Update from CMS, FDA Eyes Codeine Cough Syrups
Source: MedPageToday.com - medical news plus CME for physicians [2015.07.03]
(MedPage Today) -- Also: House members question CMS fraud prevention strategies
FDA Reviewing Safety of Codeine for Cough in Kids Under 18
Source: Medscape Emergency Medicine Headlines [2015.07.01]
The FDA is investigating the safety of using codeine-containing medicines to treat coughs and colds in children younger than 18 years because of the potential for serious adverse effects.
FDA Probes Kids' Codeine Cough Syrups
Source: MedPage Today Pediatrics [2015.07.01]
(MedPage Today) -- New European report raises questions about safety of codeine products for younger children.
Study: Whooping cough resurgence due to vaccinated people not knowing they're infectious?
Source: Immune System / Vaccines News From Medical News Today [2015.06.24]
Whooping cough has made an astonishing comeback, with 2012 seeing nearly 50,000 infections in the U.S.
Source: MedicineNet Alpha 1 Antitrypsin Deficiency Specialty [2015.06.16]
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 6/16/2015 12:00:00 AM
Published Studies Related to Guaifenesin-DM NR Liquid (Guaifenesin / Dextromethorphan)
Simultaneous determination of dextromethorphan, dextrorphan, and guaifenesin in human plasma using semi-automated liquid/liquid extraction and gradient liquid chromatography tandem mass spectrometry. [2007.01.17]
A method for the simultaneous determination of dextromethorphan (DEX), dextrorphan (DET), and guaifenesin (GG) in human plasma was developed, validated, and applied to determine plasma concentrations of these compounds in samples from six clinical pharmacokinetic (PK) studies... Pharmacokinetic data are also provided to illustrate improvements in systemic drug and metabolite concentration-time profiles that were achieved by formulation optimization.
Clinical Trials Related to Guaifenesin-DM NR Liquid (Guaifenesin / Dextromethorphan)
Placebo Controlled Trial of Dextromethorphan in Rett Syndrome [Recruiting]
Dr. Sakkubai Naidu, Principal Investigator, is initiating a double blinded placebo
controlled clinical drug trial using dextromethorphan (DM) in Rett Syndrome (RTT), at the
Pediatric Clinical Research Unit (PCRU) of the Johns Hopkins Hospital/Kennedy Krieger
Funding Source- FDA OOPD and the Johns Hopkins Institute for Clinical and Translational
It has been shown that receptors for a certain brain chemical called glutamate, in
particular the NMDA type, are increased in the brain of young RTT patients (<10 years of
age). This chemical and its receptors, when in excess, cause harmful over-stimulation of
nerve cells in the brain, contributing in part to the seizures, behavioral problems, and
learning disabilities in RTT.
The investigators propose to initiate a specific treatment using DM to counter/block the
effects of this brain chemical and its excessive receptors to improve the ill effects of
increased glutamate/NMDA receptors, because of DM's identified ability to block NMDA
receptors. DM is available for human consumption. Infants and children with respiratory
infections and cough, as well as non-ketotic hyperglycinemia, are treated with DM, which has
been well tolerated.
Combined Therapy of Methadone and Dextromethrophan [Recruiting]
The purpose of this study is to determine the pharmacological effects and outcomes of DM
therapy with this add-on study.
And to determine the immunological changes between the baseline and the end point of the
Page last updated: 2015-07-03